Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cord blood matching method could expand transplant access for blood cancer patients

NCT ID NCT01810588

Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than just cell count. The goal is to see if this matching method leads to successful engraftment and better long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem cell transplant (haploidentical donor cells and umbilical cord blood)
What this could lead to
If successful, this could make stem cell transplants safer and more available for people with blood cancers who lack a perfect donor match.
What could go wrong
This is a mid-stage trial with 270 participants, so results are not yet proven. The procedure carries risks like infection, graft failure, and side effects from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

270 people

The number who actually took part.

Started

Oct 2012

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must have a confirmed diagnosis of: 1. Previously Relapsed or refractory acute leukemia (myeloid or lymphoid) 2. Acute leukemia in first remission at high-risk for recurrence 3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis 4. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma 5. Chronic lymphocytic leukemia, relapsed or with poor prognostic features 6. Multiple myeloma 7. Myelodysplastic syndrome 8. Chronic myeloproliferative disease 9. Hemoglobinopathies 10. Aplastic anemia 11. Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm) * Age ≥ 18 years * Likely to benefit from allogeneic transplant in the opinion of the transplant physician * An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame. * Karnofsky (KPS) Performance status of \>= 70% * Acceptable organ function as defined below: Serum bilirubin: \< 2.0mg/dL ALT(SGPT): \< 3 X upper limit of normal Creatinine Clearance: \> 50 mL/min/1.73m2 (as estimated by the modified MDRD equation) * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Life expectancy is severely limited by concomitant illness or uncontrolled infection * Severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFT's) * Evidence of chronic active hepatitis or cirrhosis * Uncontrolled HIV disease * Pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia aplastic anemia B-cell chronic lymphocytic leukemia CD4+/CD56+ hematodermic neoplasm chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid system neoplasm hemoglobinopathy Hodgkins lymphoma lymphoma lymphosarcoma myelodysplastic syndrome Myeloproliferative Disorders myeloproliferative neoplasm plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancies

Contacts and locations

Locations

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.